©istock.com/Andrea Obzerova
Interdisciplinary CompetenceMolecular Diagnostics
Know how in the analysis of genetic material.
For the benefit of patients.

IllnessEpilepsy, early infantile; differential diagnosis

Summary

Short information

Comprehensive differential diagnostic panel for Epilepsy, infantile comprising 8 guideline-curated and altogether 169 curated genes according to the clinical signs

ID
EP0370
Number of genes
104 Accredited laboratory test
Examined sequence length
24,3 kb (Core-/Core-canditate-Genes)
254,7 kb (Extended panel: incl. additional genes)
Analysis Duration
on request
Test material
  • EDTA-anticoagulated blood (3-5 ml)
Diagnostic indications

NGS +

[Sanger]

 

Gene panel

Selected genes

NameExon Length (bp)OMIM-GReferenz-Seq.Heredity
CDKL53093NM_003159.3XL
GABRG21404NM_000816.3AD
PCDH193447NM_001184880.2XL
SCN1A6030NM_001165963.4AD
SCN2A6018NM_021007.3AD
SLC25A22972NM_024698.6AR, AD
SLC2A11479
  • No OMIM-Gs linked
NM_006516.4AD, AR
STXBP11812NM_003165.6AD, AR
AARS12927NM_001605.3AR
ADAR2796NM_001111.5AR
ALDH7A11620NM_001182.5AR
AP3B23249NM_004644.5AR
ARHGEF91551NM_015185.3XL
ARV1816NM_022786.3AR
ASAH11188NM_177924.5AR
ATP1A33042NM_152296.5AD
CACNA1A6786NM_001127221.2AD, AR
CACNB41563NM_000726.5AD, AR
CHD25487NM_001271.4AD
CLN6936NM_017882.3AR
CNPY3837NM_006586.5AR
CNTNAP23996NM_014141.6AR
CPA61314NM_020361.5AD, AR
CUX24461NM_015267.4AD
DENND5A3864NM_015213.4AR
DNAJC5597NM_025219.3AR
DNM12595NM_004408.4AD
DOCK76390NM_001271999.2AR
DYRK1A2292NM_001396.5AD
EEF1A21392NM_001958.5AD
FOLR1774NM_016725.3AR
FOXG11470NM_005249.5AD
FRRS1L1035NM_014334.4AR
GABBR22826NM_005458.8AD
GABRA11371NM_000806.5AD
GABRA21356NM_001114175.3AD
GABRA51389NM_000810.4AD
GABRB21603NM_021911.3AD
GABRB31422NM_000814.6AD
GNAO11065NM_020988.3AD
GOSR2639NM_004287.5AR
GRIN12817NM_007327.4AD, AR
GRIN2A4395NM_000833.5AD
GRIN2B4455NM_000834.5AD
HCN12673NM_021072.4AD
HCN22670NM_001194.4AD, AR
HNRNPU2478NM_031844.3AD
IER3IP1249NM_016097.5AR
IFIH13078NM_022168.4AD
ITPA585NM_033453.4AR
KCNA21500NM_004974.4AD
KCNB12577NM_004975.4AD
KCNJ101140NM_002241.5AR
KCNQ22619NM_172107.4AD
KCNQ32619NM_004519.4AD
KCNT13708NM_020822.3AD
KCTD7870NM_153033.5AR
MBD54485NM_018328.5AD
MDH21017NM_005918.4AR
MECP21461NM_004992.4XL
MEF2C1422NM_002397.5AD
NRXN14644NM_001135659.3AR, AD
NTRK22517NM_006180.6AD
OCLN1569NM_002538.4AR
PARS21428NM_152268.4AR
PDHX1506NM_003477.3AR
PIGA1455NM_002641.4XLR
PIGB1699NM_004855.5AR
PIGN2796NM_176787.5AR
PIGQ1746NM_004204.5AR
PIGT1737NM_015937.6AR
PLCB13651NM_015192.4AR
PNKP1566NM_007254.4AR
PNPO786NM_018129.4AR
POLG3720NM_002693.3AR
PRICKLE12496NM_153026.3AR
PRRT21023NM_145239.3AD
RNASEH2A900NM_006397.3AR
RNASEH2B939NM_024570.4AR
RNASEH2C495NM_032193.4AR
SAMHD11881NM_015474.4AR
SCN1B657NM_001037.5AD, AR
SCN3A6003NM_006922.4AD
SCN8A5943NM_014191.4AD
SCN9A5934NM_002977.3AD, AR
SLC12A53351NM_020708.5AD, AR
SLC13A51707NM_177550.5AR
SLC1A21725NM_004171.4AD, AR
SLC25A122037NM_003705.5AR
SLC35A21182NM_001042498.3XL
SLC9A62010NM_006359.3XL
SMS942NM_004595.5XLR
SPTAN17434NM_001130438.3AD
ST3GAL51188NM_003896.4AR
STX1B867NM_052874.5AD
SYNGAP14032NM_006772.3AD
SYNJ14839NM_003895.3AR
SZT210128NM_015284.4AR
TBC1D241680NM_001199107.2AR
TCF42016NM_001083962.2AD
TPP11692NM_000391.4AR
TRAK12862NM_001042646.3AR
TREX1945NM_033629.6AD, AR
WWOX1245NM_016373.4AR

Informations about the disease

Clinical Comment

Epilepsy can arise from a variety of genetic, structural, metabolic, immunologic, infectious or unknown causes. Most of the recognized genetic epilepsies begin in childhood. Genetic epilepsies include the well-characterized syndromes of generalized epilepsies, often associated with impaired brain development and refractory seizures, such as Dravet syndrome. Other infantile syndromes and other epilepsy entities include febrile seizures [plus] as well as epilepsy of infancy with wandering focal seizures, West syndrome, myoclonic epilepsy, benign familial infantile epilepsy and myoclonic encephalopathy in nonprogressive disorders. In total, around 100 genetic forms of early infantile epilepsies have been defined, and all inheritance traits are represented. Penetrance rates are low to complete, depending on the mutated gene, and expressivity can sometimes vary quite substantially, even in the same family. Using DNA panel analysis, a yield of up to 25% can be achieved in cases with unknown etiology. Therefore, inconspicuous findings do not exclude clinical diagnosis.

References: https://www.ncbi.nlm.nih.gov/books/NBK1318/

Leitlinie: Diagnostische Prinzipien bei Epilepsien des Kindesalters; S1; From: 18.12.2017, valid until 17.12.2022; Gesellschaft für Neuropädiatrie (GNP): "Zwar haben die neuesten molekulargenetischen Befunde beigetragen, die Ursachen dieser häufigen idiopathischen Epilepsien etwas besser zu verstehen, doch ist eine routinemäßige genetische Diagnostik derzeit noch nicht sinnvoll.." However GRIN2A, KCNT1, KCNQ2, KCNQ3, SCN1A genes explicitly mentioned.

 

Synonyms
  • Alias: Childhood-onset epilepsy syndrome
  • Alias: Infantile spasms syndrome/West syndrome
  • Allelic: Alternating hemiplegia of childhood 1 (ATP1A2)
  • Allelic: Arthrogryposis, cleft palate, craniosynostosis, impaired intellectual development (PPP3CA)
  • Allelic: Chilblain lupus 2 (SAMHD1)
  • Allelic: Cognitive impairment with/-out cerebellar ataxia (SCN8A)
  • Allelic: Cutis laxa, AR, type IID (ATP6V1A)
  • Allelic: Deafness, AD 71 (DMXL2)
  • Allelic: Endocrine-cerebroosteodysplasia (CI1)
  • Allelic: Episodic ataxia, type 5 (CACNB4)
  • Allelic: Fetal akinesia, respiratory insuff., microceph., polymicrogyria, dysmorphic face (ATP1A2)
  • Allelic: Global developmental delay, progressive ataxia + elevated glutamine (GLS)
  • Allelic: Hydranencephaly with abnormal genitalia (ARX)
  • Allelic: Hyperaldosteronism, familial, type II (CLCN2)
  • Allelic: Hyperaldosteronism, familial, type IV (CACNA1H)
  • Allelic: Infantile cataract, skin abnormalities, glutamate excess, impaired intell. developm. (GLS)
  • Allelic: Intellectual developmental disorder, AR 12 (ST3GAL3)
  • Allelic: Migraine, familial basilar (ATP1A2)
  • Allelic: Migraine, familial hemiplegic, 2 (ATP1A2)
  • Allelic: Neuropathy, hereditary sensory + autonomic, type IID (SCN9A)
  • Allelic: Obesity, hyperphagia + developmental delay (NTRK2)
  • Allelic: Paroxysmal nocturnal hemoglobinuria 2 (PIGT)
  • Allelic: Paroxysmal nocturnal hemoglobinuria, somatic (PIGA)
  • Allelic: Polyendocrine-polyneuropathy syndrome (DMXL2)
  • Allelic: Progressive external ophthalmoplegia, AD 1/AR 1 (POLG)
  • Allelic: Small fiber neuropathy (SCN9A)
  • Allelic: Spinocerebellar ataxia, AR 12 (WWOX)
  • Allelic: Spinocerebellar ataxia, AR 24 (UBA5)
  • Allelic: Usher syndrome, type 2C (ADGRV1)
  • Aicardi-Goutieres syndrome 1, AD/AR (TREX1)
  • Aicardi-Goutieres syndrome 2 (RNASEH2B)
  • Aicardi-Goutieres syndrome 3 (RNASH2C)
  • Aicardi-Goutieres syndrome 4 (RNASH2A)
  • Aicardi-Goutieres syndrome 5 (SAMHD1)
  • Aicardi-Goutieres syndrome 6 (ADAR1)
  • Aicardi-Goutieres syndrome 7 (IFIH1)
  • Cerebellar atrophy, developmental delay + seizures (KCNMA1)
  • Ceroid lipofuscinosis, neuronal, 1 (PPT1)
  • Ceroid lipofuscinosis, neuronal, 10 (CTSD)
  • Ceroid lipofuscinosis, neuronal, 11 (GRN)
  • Ceroid lipofuscinosis, neuronal, 13 (Kufs type), AD (CTSF)
  • Ceroid lipofuscinosis, neuronal, 2 (TPP1)
  • Ceroid lipofuscinosis, neuronal, 3 (CLN3)
  • Ceroid lipofuscinosis, neuronal, 4, Kufs type (DNAJC5)
  • Ceroid lipofuscinosis, neuronal, 5 (CLN5)
  • Ceroid lipofuscinosis, neuronal, 6A (CLN6)
  • Ceroid lipofuscinosis, neuronal, 6B, Kufs type (CLN6)
  • Ceroid lipofuscinosis, neuronal, 7 (MFSD8)
  • Ceroid lipofuscinosis, neuronal, 8 (CLN8)
  • Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant (CLN8)
  • Chromosome 5q14.3 deletion syndrome (MEF2C)
  • Cone-rod synaptic disorder, congenital nonprogressive (CABP4)
  • Congenital disorder of glycosylation, type IIm (SLC35A2)
  • Convulsions, familial infantile, with paroxysmal choreoathetosis (PRRT2)
  • Cornelia de Lange syndrome 2 (SMC1A)
  • Cortical dysplasia-focal epilepsy syndrome (CNTNAP2)
  • DOORS syndrome (TBC1D24)
  • Developmental + epileptic encephalopathy 1 (ARX)
  • Developmental + epileptic encephalopathy 103 (KCNC2)
  • Developmental + epileptic encephalopathy 12 (PLCB1)
  • Developmental + epileptic encephalopathy 13 (SCN8A)
  • Developmental + epileptic encephalopathy 14 (KCNT1)
  • Developmental + epileptic encephalopathy 15 (ST3GAL3)
  • Developmental + epileptic encephalopathy 16 (TBC1D24)
  • Developmental + epileptic encephalopathy 17 (GNAO1)
  • Developmental + epileptic encephalopathy 18 (SZT2)
  • Developmental + epileptic encephalopathy 19 (GABRA1)
  • Developmental + epileptic encephalopathy 21 (NECAP1)
  • Developmental + epileptic encephalopathy 23 (DOCK7)
  • Developmental + epileptic encephalopathy 24 (HCN1)
  • Developmental + epileptic encephalopathy 25, with amelogenesis imperfecta (SLC13A5)
  • Developmental + epileptic encephalopathy 26 (KCNB1)
  • Developmental + epileptic encephalopathy 27 (GRIN2B)
  • Developmental + epileptic encephalopathy 28 (WWOX)
  • Developmental + epileptic encephalopathy 29 (AARS1)
  • Developmental + epileptic encephalopathy 31 (DNM1)
  • Developmental + epileptic encephalopathy 32 (KCNA2)
  • Developmental + epileptic encephalopathy 33 (EEF1A2)
  • Developmental + epileptic encephalopathy 34 (SLC12A5)
  • Developmental + epileptic encephalopathy 35 (ITPA)
  • Developmental + epileptic encephalopathy 36 (ALG13)
  • Developmental + epileptic encephalopathy 37 (FRRS1L)
  • Developmental + epileptic encephalopathy 38 (ARV1)
  • Developmental + epileptic encephalopathy 39 (SLC25A12)
  • Developmental + epileptic encephalopathy 41 (SLC1A2)
  • Developmental + epileptic encephalopathy 42 (CACNA1A)
  • Developmental + epileptic encephalopathy 44 (UBA5)
  • Developmental + epileptic encephalopathy 46 (GRIN2D)
  • Developmental + epileptic encephalopathy 47 (FGF12)
  • Developmental + epileptic encephalopathy 48 (AP3B2)
  • Developmental + epileptic encephalopathy 49 (DENND5A)
  • Developmental + epileptic encephalopathy 5 (SPTAN1)
  • Developmental + epileptic encephalopathy 51 (MDH2)
  • Developmental + epileptic encephalopathy 52 (SCN1B)
  • Developmental + epileptic encephalopathy 53 (SYNJ1)
  • Developmental + epileptic encephalopathy 54 (HNRNPU)
  • Developmental + epileptic encephalopathy 56 (YWHAG)
  • Developmental + epileptic encephalopathy 57 (KCNT2)
  • Developmental + epileptic encephalopathy 58 (NTRK2)
  • Developmental + epileptic encephalopathy 59 (GABBR2)
  • Developmental + epileptic encephalopathy 60 (CNPY3)
  • Developmental + epileptic encephalopathy 62 (SCN3A)
  • Developmental + epileptic encephalopathy 64 (RHOBTB2)
  • Developmental + epileptic encephalopathy 65 (CYFIP2)
  • Developmental + epileptic encephalopathy 66 (PACS2)
  • Developmental + epileptic encephalopathy 67 (CUX2)
  • Developmental + epileptic encephalopathy 68 (TRAK1)
  • Developmental + epileptic encephalopathy 69 (CACNA1E)
  • Developmental + epileptic encephalopathy 7 (KCNQ2)
  • Developmental + epileptic encephalopathy 70 (PHACTR1)
  • Developmental + epileptic encephalopathy 71 (GLS)
  • Developmental + epileptic encephalopathy 75 (PARS2)
  • Developmental + epileptic encephalopathy 76 (ACTL6B)
  • Developmental + epileptic encephalopathy 77 (PIGQ)
  • Developmental + epileptic encephalopathy 78 (GABRA2)
  • Developmental + epileptic encephalopathy 79 (GABRA5)
  • Developmental + epileptic encephalopathy 8 (ARHGEF9)
  • Developmental + epileptic encephalopathy 80 (PIGB)
  • Developmental + epileptic encephalopathy 81 (DMXL2)
  • Developmental + epileptic encephalopathy 82 (GOT2)
  • Developmental + epileptic encephalopathy 85, with/-out midline brain defects (SMC1A)
  • Developmental + epileptic encephalopathy 89 (GAD1)
  • Developmental + epileptic encephalopathy 90 (FGF13)
  • Developmental + epileptic encephalopathy 91 (PPP3CA)
  • Developmental + epileptic encephalopathy 92 (GABRB2)
  • Developmental + epileptic encephalopathy 93 (ATP6V1A)
  • Developmental + epileptic encephalopathy 94 (CHD2)
  • Developmental + epileptic encephalopathy 98 (ATP1A2)
  • Developmental + epileptic encephalopathy 99 (ATP1A3)
  • Dicarboxylic aminoaciduria (SLC1A1)
  • Dystonia 9 (SLC2A1)
  • Encephalopathy, familial, with neuroserpin inclusion bodies (SERPINI1)
  • Encephalopathy, neonatal severe (MECP2)
  • Enlarged vestibular aqueduct, digenic (KCNJ10)
  • Epilepsy nocturnal frontal lobe, 5 (KCNT1)
  • Epilepsy, childhood absence [Lit.] (JRK)
  • Epilepsy, childhood absence, susceptibility to, 2 (GABRG2)
  • Epilepsy, childhood absence, susceptibility to, 6 (CACNNA1H)
  • Epilepsy, familial focal, with variable foci 1 (DDEPDC5)
  • Epilepsy, familial focal, with variable foci 2 (NPRL2)
  • Epilepsy, familial focal, with variable foci 3 (NPRL3)
  • Epilepsy, familial focal, with variable foci 4 (SCN3A)
  • Epilepsy, familial temporal lobe, 1 (LGI1)
  • Epilepsy, familial temporal lobe, 5 (CPA6)
  • Epilepsy, familial temporal lobe, 7 (RELN)
  • Epilepsy, focal, with speech disorder with/-out impaired intellectual development (GRIN2A)
  • Epilepsy, generalized, with febrile seizures plus, type 2 (SCN1A)
  • Epilepsy, generalized, with febrile seizures plus, type 3 (GABRG2)
  • Epilepsy, idiopathic generalized, 10 (GABRD)
  • Epilepsy, idiopathic generalized, susceptibility to, 11 (CLCN2)
  • Epilepsy, idiopathic generalized, susceptibility to, 12 (SLC2A1)
  • Epilepsy, idiopathic generalized, susceptibility to, 14 (SLC12A5)
  • Epilepsy, idiopathic generalized, susceptibility to, 15 (RORB)
  • Epilepsy, idiopathic generalized, susceptibility to, 16 (KCNMA1)
  • Epilepsy, idiopathic generalized, susceptibility to, 17 (HCN2)
  • Epilepsy, idiopathic generalized, susceptibility to, 6 (CACNA1H)
  • Epilepsy, idiopathic generalized, susceptibility to, 9 (CACNB4)
  • Epilepsy, juvenile absence, susceptibility to, 1 (EFHC1)
  • Epilepsy, juvenile absence, susceptibility to, 2 (CLCN2)
  • Epilepsy, juvenile myoclonic, susceptibility to (GABRD)
  • Epilepsy, juvenile myoclonic, susceptibility to, 10 (CILK1)
  • Epilepsy, juvenile myoclonic, susceptibility to, 6 (CACNB4)
  • Epilepsy, juvenile myoclonic, susceptibility to, 8 (CLCN2)
  • Epilepsy, nocturnal frontal lobe, 1 (CHRNA4)
  • Epilepsy, nocturnal frontal lobe, 3 (CHRNB2)
  • Epilepsy, nocturnal frontal lobe, type 4 (CHRNA2)
  • Epilepsy, progressive myoclonic 1A, Unverricht and Lundborg (CSTB)
  • Epilepsy, progressive myoclonic 1B (PRICKLE1)
  • Epilepsy, progressive myoclonic 2A, Lafora (EPM2A)
  • Epilepsy, progressive myoclonic 2B, Lafora (NHLRC1)
  • Epilepsy, progressive myoclonic 3, with/-out intracellular inclusions (KCTD7)
  • Epilepsy, progressive myoclonic 4, with/-out renal failure (SCARB2)
  • Epilepsy, progressive myoclonic 6 (GOSR2)
  • Epilepsy, progressive myoclonic 7 (KCNC1)
  • Epilepsy, progressive myoclonic, 10 (PRDM8)
  • Epilepsy, progressive myoclonic, 8 (CERS1)
  • Epilepsy, progressive myoclonic, 9 (LMNB2)
  • Epilepsy, pyridoxine-dependent (ALDH7A1)
  • Epilepsy, rolandic, with proxysmal exercise-induce dystonia + writer's cramp (TBC1D24)
  • Epileptic encephalopathy Lennox-Gastaut type [panelapp] (MAPK10)
  • Epileptic encephalopathy, early infantile, 11 (SCN2A)
  • Epileptic encephalopathy, early infantile, 2 (CDKL5)
  • Epileptic encephalopathy, early infantile, 3 (SLC25A22)
  • Epileptic encephalopathy, early infantile, 4 (STXBP1)
  • Epileptic encephalopathy, early infantile, 6 [Dravet syndrome] (SCN1A)
  • Epileptic encephalopathy, early infantile, 74 (GABRG2)
  • Epileptic encephalopathy, early infantile, 9 (GABRG2)
  • Episodic ataxia, type 9 (SCN2A)
  • Episodic kinesigenic dyskinesia 1 (PRRT2)
  • Farber lipogranulomatosis (ASAH1)
  • Febrile seizures, familial, 11 (CPA6)
  • Febrile seizures, familial, 2 (HCN2)
  • Febrile seizures, familial, 3A (SCN1A)
  • Febrile seizures, familial, 4 (ADGRV1)
  • Febrile seizures, familial, 8 (GABRG2)
  • GLUT1 deficiency syndrome 1, infantile onset, severe (SLC2A1)
  • GLUT1 deficiency syndrome 2, childhood onset (SLC2A1)
  • Generalized epilepsy with febrile seizures plus, type 1 (SCN1B)
  • Generalized epilepsy with febrile seizures plus, type 10 (HCN1)
  • Generalized epilepsy with febrile seizures plus, type 11 (HCN2)
  • Generalized epilepsy with febrile seizures plus, type 5, susceptibility to (GABRD)
  • Generalized epilepsy with febrile seizures plus, type 9 (STX1B)
  • Insensitivity to pain, congenital (SCN9A)
  • Intellectual developmental disorder 60 with seizures (AP2M1)
  • Intellectual developmental disorder with severe speech + ambulation defects (ACTL6B)
  • Intellectual developmental disorder, AD 6, with/-out seizures (GRIN2B)
  • Intellectual developmental disorder, XL 29 (ARX)
  • Intellectual developmental disorder, XL 98 (NEXMIF)
  • Intellectual developmental disorder, XL syndromic, Christianson type (SLC9A6)
  • Intellectual developmental disorder, XL syndromic, Lubs type (MECP2)
  • Intellectual developmental disorder, XL syndromic, Snyder-Robinson type (SMS)
  • Intellectual developmental disorder, XL, syndromic 13 (MECP2)
  • Intractable infantile spasms [Lit.] (CRH)
  • Lacticacidemia due to PDX1 deficiency (PDHX)
  • Leukoencephalopathy with ataxia (CLCN2)
  • Liang-Wang syndrome (KCNMA1)
  • Lissencephaly 1 (PAHFA1B1)
  • Lissencephaly 2, Norman-Roberts type (RELN)
  • Lissencephaly, XL (DCX)
  • Lissencephaly, XL 2 (ARX)
  • Mental retardation, AD 1 (MBD5)
  • Mental retardation, AD 38 (EEF1A2)
  • Mental retardation, AD 5 (SYNGAP1)
  • Mental retardation, AD 7 (DYRK1A)
  • Microcephaly, epilepsy + diabetes syndrome (IER3IP1)
  • Microcephaly, seizures + developmental delay (PNKP)
  • Migraine, familial hemiplegic, 3 (SCN1A)
  • Mitochondrial DNA depletion syndrome 4A, Alpers type (POLG)
  • Mitochondrial DNA depletion syndrome 4B, MNGIE type (POLG)
  • Mitochondrial recessive ataxia syndrome, includes SANDO + SCAE (POLG)
  • Multiple congenital anomalies-hypotonia-seizures syndrome 1 (PIGN)
  • Multiple congenital anomalies-hypotonia-seizures syndrome 2 (PIGA)
  • Multiple congenital anomalies-hypotonia-seizures syndrome 3 (PIGT)
  • Myoclonic epilepsy, infantile, familial (TBC1D24)
  • Myoclonic epilepsy, juvenile, susceptibility to, 1 (EFHC1)
  • Myoclonic-atonic epilepsy (SLC6A1)
  • Myoclonus, familial, 2 (SCN8A)
  • Myokymia (KCNQ2)
  • Neurodegeneration due to cerebral folate transport deficiency (FOLR1)
  • Neurodevelopmental delay, behavioral difficulties + epilepsy [Lit.] (PRICKLE2)
  • Neurodevelopmental disorder with hypotonia, stereotypic hand movements, impaired language (MEF2C)
  • Neurodevelopmental disorder with involuntary movements (GNAO1)
  • Neurodevelopmental disorder with/-out hyperkinetic movements + seizures, AD/AR (GRIN1)
  • Parkinson disease 20, early-on (SYNJ1)
  • Paroxysmal extreme pain disorder (SCN9A)
  • Paroxysmal nonkinesigenic dyskinesia, 3, with or without generalized epilepsy (KCNMA1)
  • Partington syndrome (ARX)
  • Pitt-Hopkins syndrome (TCF4)
  • Pitt-Hopkins-like syndrome 1 (CNTNAP2)
  • Pitt-Hopkins-like syndrome 2 (NRXN1)
  • Proud syndrome (ARX)
  • Pseudo-TORCH syndrome 1 (OCLN)
  • Pyridoxamine 5'-phosphate oxidase deficiency (PNPO)
  • Rett syndrome (MECP2)
  • Rett syndrome, atypical (MECP2)
  • Rett syndrome, congenital variant (FOXG1)
  • Rett syndrome, preserved speech variant (MECP2)
  • Rolandic epilepsy, impaired intellectual development + speech dyspraxia (SRPX2)
  • SESAME syndrome (KCNJ10)
  • Salt + pepper developmental regression syndrome (ST3GAL5)
  • Seizures, benign familial infantile, 2 (PRRT2)
  • Seizures, benign familial infantile, 3 (SCN2A)
  • Seizures, benign familial infantile, 5 (SCN8A)
  • Seizures, benign neonatal, 1 (KCNQ2)
  • Seizures, benign neonatal, 2 (KCNQ3)
  • Singleton-Merten syndrome 1 (IFIH1)
  • Spinal muscular atrophy with progressive myoclonic epilepsy (ASAH1)
  • Stomatin-deficient cryohydrocytosis with neurologic defects (SLC2A1)
  • Subcortical laminal heterotopia, XL (DCX)
  • Subcortical laminar heterotopia (PAHFA1B1)
Heredity, heredity patterns etc.
  • AD
  • AR
  • XL
  • XLR
OMIM-Ps
  • Multiple OMIM-Ps
ICD10 Code

Bioinformatics and clinical interpretation

Test-Stärken

  • DAkkS-akkreditiertes Labor
  • EU-Richtlinie für IVD in Umsetzung
  • Qualitäts-kontrolliert arbeitendes Personal
  • Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
  • Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
  • eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
  • unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
  • unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
  • unsere umfassenden klinischen Aussagen

Testeinschränkungen

  • Gene mit eingeschränkter Abdeckung werden gekennzeichnet
  • Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
  • es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
  • die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
  • Gen-Konversionen
  • komplexe Inversionen
  • Balancierte Translokationen
  • Mitochondriale Varianten
  • Repeat-Expansionen, sofern nicht anders dokumentiert
  • nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
  • niedriger Mosaik-Status
  • Repeat-Blöcke von Mononukleotiden
  • Indels >50bp (Insertionen-Deletionen)
  • Deletionen oder Duplikationen einzelner Exons
  • Varianten innerhalb von Pseudogenen
  • die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde

Laboratory requirement

  • Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.

  • Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.

  • Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.

  • Die Untersuchung wird auch für Selbstzahler angeboten.